blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2340837

EP2340837 - COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS [Right-click to bookmark this link]
Former [2011/27]Combination treatment of cancer comprising EGFR/HER2 inhibitors
[2016/43]
StatusNo opposition filed within time limit
Status updated on  19.01.2018
Database last updated on 11.09.2024
FormerThe patent has been granted
Status updated on  10.02.2017
FormerGrant of patent is intended
Status updated on  01.02.2017
Most recent event   Tooltip06.03.2020Lapse of the patent in a contracting state
New state(s): TR		published on 08.04.2020  [2020/15]
Applicant(s)For:AT  BE  BG  CH  CY  CZ  DK  EE  ES  FI  FR  GB  GR  HU  IE  IS  IT  LI  LT  LU  LV  MC  NL  PL  PT  RO  SE  SI  SK  TR 
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein / DE
For:DE 
Boehringer Ingelheim Pharma GmbH & Co. KG
Binger Strasse 173
55216 Ingelheim am Rhein / DE
[2011/27]
Inventor(s)01 / Solca, Flavio
Gesslsgasse 10/6
1230, Wien / AT
02 / Amelsberg, Andree
4 Rolf's Drive
Danbury, CT 06810 / US
03 / Van Meel, Jacobus C.A.
Kaerntnergasse 6
2340, Moedling / AT
04 / Baum, Anke
Hoeglmuellergasse 4/8
1050, Wien / AT
05 / Stehle, Gerd
Jahnstr. 1
89584, Ehingen / DE
 [2017/11]
Former [2011/27]01 / Solca, Flavio
Gesslsgasse 10/6
1230, Wien / AT
02 / Amelsberg, Andree
4 Rolf's Drive
Danbury, CT 06810 / US
03 / Van Meel, Jacobus C.A.
Kaerntnergasse 6
2340, Moedling / AT
04 / Baum, Anke
Hoeglmuellergasse 4/8
1050, Wien / AT
05 / Stehle, Gerd
Jahnstr. 1
89584, Ehingen / DE
Representative(s)Simon, Elke Anna Maria, et al
Boehringer Ingelheim GmbH
Binger Strasse 173
55216 Ingelheim am Rhein / DE
[2012/40]
Former [2011/27]Hammann, Heinz, et al
Boehringer Ingelheim GmbH Corporate Patents Binger Strasse 173
55216 Ingelheim am Rhein / DE
Application number, filing date11155582.709.11.2006
[2011/27]
Priority number, dateEP2005011066911.11.2005         Original published format: EP 05110669
[2011/27]
Previously filed application, dateEP2006081938009.11.2006
[2011/27]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2340837
Date:06.07.2011
Language:EN
[2011/27]
Type: B1 Patent specification 
No.:EP2340837
Date:15.03.2017
Language:EN
[2017/11]
Search report(s)(Supplementary) European search report - dispatched on:EP24.05.2011
ClassificationIPC:A61K31/337, A61P35/00
[2016/43]
CPC:
C07D405/12 (EP,US); A61K31/00 (US); A61K31/337 (EP,US);
A61K31/517 (EP,US); A61K39/39558 (US); A61K45/06 (EP,US);
A61P35/00 (EP); A61P35/02 (EP) (-)
C-Set:
A61K31/00, A61K2300/00 (US);
A61K31/337, A61K2300/00 (US,EP);
A61K31/517, A61K2300/00 (US,EP)
Former IPC [2016/42]A61K31/337
Former IPC [2011/27]A61K31/517, A61K31/00, A61P35/00
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2017/11]
Former [2011/27]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  NL,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:KOMBINATIONSBEHANDLUNG GEGEN KREBS MIT EGFR/HER2-HEMMERN[2016/36]
English:COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS[2016/43]
French:TRAITEMENT COMBINÉ DU CANCER COMPRENANT DES INHIBITEURS EGFR/HER2[2016/43]
Former [2011/27]Kombinationsbehandlung gegen Krebs mit EGFR/HER2-Hemmern
Former [2011/27]Combination treatment of cancer comprising EGFR/HER2 inhibitors
Former [2011/27]Traitement combiné du cancer comprenant des inhibiteurs de EGFR/HER2
Examination procedure30.12.2011Amendment by applicant (claims and/or description)
09.01.2012Examination requested  [2012/08]
20.11.2013Despatch of a communication from the examining division (Time limit: M06)
26.06.2014Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
20.08.2014Reply to a communication from the examining division
17.11.2015Despatch of a communication from the examining division (Time limit: M04)
18.03.2016Reply to a communication from the examining division
28.09.2016Communication of intention to grant the patent
30.01.2017Fee for grant paid
30.01.2017Fee for publishing/printing paid
30.01.2017Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP06819380.4  / EP1948180
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20060819380) is  25.02.2009
Opposition(s)18.12.2017No opposition filed within time limit [2018/08]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
20.08.2014Request for further processing filed
20.08.2014Full payment received (date of receipt of payment)
Request granted
29.08.2014Decision despatched
Fees paidRenewal fee
24.06.2011Renewal fee patent year 03
24.06.2011Renewal fee patent year 04
24.06.2011Renewal fee patent year 05
30.11.2011Renewal fee patent year 06
30.11.2012Renewal fee patent year 07
02.12.2013Renewal fee patent year 08
01.12.2014Renewal fee patent year 09
30.11.2015Renewal fee patent year 10
30.11.2016Renewal fee patent year 11
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU09.11.2006
AT15.03.2017
CY15.03.2017
CZ15.03.2017
DK15.03.2017
EE15.03.2017
ES15.03.2017
FI15.03.2017
IT15.03.2017
LT15.03.2017
LV15.03.2017
MC15.03.2017
NL15.03.2017
PL15.03.2017
RO15.03.2017
SE15.03.2017
SI15.03.2017
SK15.03.2017
TR15.03.2017
BG15.06.2017
GR16.06.2017
IS15.07.2017
PT17.07.2017
IE09.11.2017
LU09.11.2017
BE30.11.2017
CH30.11.2017
LI30.11.2017
[2020/15]
Former [2019/46]HU09.11.2006
AT15.03.2017
CY15.03.2017
CZ15.03.2017
DK15.03.2017
EE15.03.2017
ES15.03.2017
FI15.03.2017
IT15.03.2017
LT15.03.2017
LV15.03.2017
MC15.03.2017
NL15.03.2017
PL15.03.2017
RO15.03.2017
SE15.03.2017
SI15.03.2017
SK15.03.2017
BG15.06.2017
GR16.06.2017
IS15.07.2017
PT17.07.2017
IE09.11.2017
LU09.11.2017
BE30.11.2017
CH30.11.2017
LI30.11.2017
Former [2019/31]HU09.11.2006
AT15.03.2017
CZ15.03.2017
DK15.03.2017
EE15.03.2017
ES15.03.2017
FI15.03.2017
IT15.03.2017
LT15.03.2017
LV15.03.2017
MC15.03.2017
NL15.03.2017
PL15.03.2017
RO15.03.2017
SE15.03.2017
SI15.03.2017
SK15.03.2017
BG15.06.2017
GR16.06.2017
IS15.07.2017
PT17.07.2017
IE09.11.2017
LU09.11.2017
BE30.11.2017
CH30.11.2017
LI30.11.2017
Former [2018/50]AT15.03.2017
CZ15.03.2017
DK15.03.2017
EE15.03.2017
ES15.03.2017
FI15.03.2017
IT15.03.2017
LT15.03.2017
LV15.03.2017
MC15.03.2017
NL15.03.2017
PL15.03.2017
RO15.03.2017
SE15.03.2017
SI15.03.2017
SK15.03.2017
BG15.06.2017
GR16.06.2017
IS15.07.2017
PT17.07.2017
IE09.11.2017
LU09.11.2017
BE30.11.2017
CH30.11.2017
LI30.11.2017
Former [2018/45]AT15.03.2017
CZ15.03.2017
DK15.03.2017
EE15.03.2017
ES15.03.2017
FI15.03.2017
IT15.03.2017
LT15.03.2017
LV15.03.2017
MC15.03.2017
NL15.03.2017
PL15.03.2017
RO15.03.2017
SE15.03.2017
SI15.03.2017
SK15.03.2017
BG15.06.2017
GR16.06.2017
IS15.07.2017
PT17.07.2017
IE09.11.2017
LU09.11.2017
CH30.11.2017
LI30.11.2017
Former [2018/41]AT15.03.2017
CZ15.03.2017
DK15.03.2017
EE15.03.2017
ES15.03.2017
FI15.03.2017
IT15.03.2017
LT15.03.2017
LV15.03.2017
MC15.03.2017
NL15.03.2017
PL15.03.2017
RO15.03.2017
SE15.03.2017
SI15.03.2017
SK15.03.2017
BG15.06.2017
GR16.06.2017
IS15.07.2017
PT17.07.2017
LU09.11.2017
CH30.11.2017
LI30.11.2017
Former [2018/33]AT15.03.2017
CZ15.03.2017
DK15.03.2017
EE15.03.2017
ES15.03.2017
FI15.03.2017
IT15.03.2017
LT15.03.2017
LV15.03.2017
MC15.03.2017
NL15.03.2017
PL15.03.2017
RO15.03.2017
SE15.03.2017
SI15.03.2017
SK15.03.2017
BG15.06.2017
GR16.06.2017
IS15.07.2017
PT17.07.2017
CH30.11.2017
LI30.11.2017
Former [2018/14]AT15.03.2017
CZ15.03.2017
DK15.03.2017
EE15.03.2017
ES15.03.2017
FI15.03.2017
IT15.03.2017
LT15.03.2017
LV15.03.2017
NL15.03.2017
PL15.03.2017
RO15.03.2017
SE15.03.2017
SI15.03.2017
SK15.03.2017
BG15.06.2017
GR16.06.2017
IS15.07.2017
PT17.07.2017
Former [2018/09]AT15.03.2017
CZ15.03.2017
DK15.03.2017
EE15.03.2017
ES15.03.2017
FI15.03.2017
IT15.03.2017
LT15.03.2017
LV15.03.2017
NL15.03.2017
PL15.03.2017
RO15.03.2017
SE15.03.2017
SK15.03.2017
BG15.06.2017
GR16.06.2017
IS15.07.2017
PT17.07.2017
Former [2017/51]AT15.03.2017
CZ15.03.2017
EE15.03.2017
ES15.03.2017
FI15.03.2017
IT15.03.2017
LT15.03.2017
LV15.03.2017
NL15.03.2017
PL15.03.2017
RO15.03.2017
SE15.03.2017
SK15.03.2017
BG15.06.2017
GR16.06.2017
IS15.07.2017
PT17.07.2017
Former [2017/50]AT15.03.2017
CZ15.03.2017
EE15.03.2017
ES15.03.2017
FI15.03.2017
IT15.03.2017
LT15.03.2017
LV15.03.2017
NL15.03.2017
PL15.03.2017
RO15.03.2017
SE15.03.2017
SK15.03.2017
BG15.06.2017
GR16.06.2017
IS15.07.2017
Former [2017/49]AT15.03.2017
CZ15.03.2017
EE15.03.2017
ES15.03.2017
FI15.03.2017
IT15.03.2017
LT15.03.2017
LV15.03.2017
NL15.03.2017
RO15.03.2017
SE15.03.2017
SK15.03.2017
BG15.06.2017
GR16.06.2017
IS15.07.2017
Former [2017/48]CZ15.03.2017
FI15.03.2017
LT15.03.2017
LV15.03.2017
NL15.03.2017
SE15.03.2017
BG15.06.2017
GR16.06.2017
Former [2017/41]FI15.03.2017
LT15.03.2017
LV15.03.2017
NL15.03.2017
SE15.03.2017
BG15.06.2017
GR16.06.2017
Documents cited:Search[XD]WO0250043  (BOEHRINGER INGELHEIM PHARMA [DE], et al) [XD] 1-35 * page 19, line 30 - page 20, line 3 *;
 [X]WO2004096224  (BOEHRINGER INGELHEIM INT [DE], et al) [X] 1-35 * page 69, line 5 - page 71, line 11 *;
 [XP]WO2006018182  (BOEHRINGER INGELHEIM INT [DE], et al) [XP] 1-6,8,15,16,29,31 * claims 1,4,14-16 *
by applicantWO0250043
 WO2004074263
 WO2005037824
 WO2004096224
 WO2004076454
    - LYNCH, NEW ENGLAND JOURNAL MEDICINE, (2004), vol. 350, page 2129
    - PAEZ, SCIENCE, (2004), vol. 304, page 1497
    - PAO, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE OF THE UNITED STATES, (2004), vol. 101, page 13306
    - KWAK, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCE OF THE UNITED STATES, (2005), vol. 102, page 7665
    - KOBAYASHI, NEW ENGLAND JOURNAL MEDICINE, (2005), vol. 352, page 786
    - Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings, (20060620), vol. 24
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.